company background image
A363250 logo

Genesystem KOSDAQ:A363250 Stock Report

Last Price

₩7.99k

Market Cap

₩58.9b

7D

-8.8%

1Y

-14.4%

Updated

26 Dec, 2024

Data

Company Financials

Genesystem Co., Ltd.

KOSDAQ:A363250 Stock Report

Market Cap: ₩58.9b

A363250 Stock Overview

A biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. More details

A363250 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Genesystem Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genesystem
Historical stock prices
Current Share Price₩7,990.00
52 Week High₩12,800.00
52 Week Low₩5,390.00
Beta0.57
1 Month Change-22.20%
3 Month Change-15.18%
1 Year Change-14.36%
3 Year Change-30.22%
5 Year Changen/a
Change since IPO-54.08%

Recent News & Updates

Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?

Feb 28
Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?

Recent updates

Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?

Feb 28
Is Genesystem (KOSDAQ:363250) Using Debt Sensibly?

Shareholder Returns

A363250KR BiotechsKR Market
7D-8.8%-2.3%-1.9%
1Y-14.4%14.9%-9.5%

Return vs Industry: A363250 underperformed the KR Biotechs industry which returned 14.9% over the past year.

Return vs Market: A363250 underperformed the KR Market which returned -9.5% over the past year.

Price Volatility

Is A363250's price volatile compared to industry and market?
A363250 volatility
A363250 Average Weekly Movement6.8%
Biotechs Industry Average Movement8.8%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.8%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A363250 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A363250's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/an/awww.genesystem.co.kr

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nucleic acid extraction assays, such as extraction kits, extraction buffers, lysis buffers, and gDNA extraction kits.

Genesystem Co., Ltd. Fundamentals Summary

How do Genesystem's earnings and revenue compare to its market cap?
A363250 fundamental statistics
Market cap₩58.93b
Earnings (TTM)-₩11.27b
Revenue (TTM)₩1.57b

35.9x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A363250 income statement (TTM)
Revenue₩1.57b
Cost of Revenue₩2.47b
Gross Profit-₩904.72m
Other Expenses₩10.36b
Earnings-₩11.27b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.60k
Gross Margin-57.76%
Net Profit Margin-719.17%
Debt/Equity Ratio13.7%

How did A363250 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:47
End of Day Share Price 2024/12/26 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genesystem Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution